Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022
12 sept. 2022 03h00 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
BioNTech und Genmab erweitern globale strategische Kollaboration zur Entwicklung und Vermarktung neuartiger Immuntherapiekandidaten
05 août 2022 06h45 HE
|
BioNTech SE
Ausweitung der Kollaboration zur Entwicklung monospezifischer Antikörperkandidaten gegen bösartige solide TumoreKollaboration nutzt Genmabs firmeneigene HexaBody®-Technologieplattform, um neuartige...
BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
05 août 2022 06h45 HE
|
BioNTech SE
Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab’s proprietary HexaBody® technology platform...
BioNTech erhält Priority-Medicines (PRIME)-Status der EMA für verstärkte regulatorische Unterstützung des CAR-T-Kandidaten BNT211 zur Behandlung von Hodenkrebs
23 juin 2022 11h00 HE
|
BioNTech SE
Erster BioNTech-Produktkandidat, der von der Europäischen Arzneimittelagentur den Priority-Medicines (PRIME)-Status erhält; dies ermöglicht eine verstärkte regulatorische Unterstützung bei der...
BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer
23 juin 2022 11h00 HE
|
BioNTech SE
First BioNTech product candidate to receive priority medicines (PRIME) designation by the European Medicines Agency for enhanced regulatory support facilitating the clinical development of the...
Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference
06 mai 2022 11h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N. J. , May 06, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that...
BioNTech präsentiert erste positive Daten der Phase-1/2-Studie mit erstem CAR-T-Programm BNT211 auf der AACR
11 avr. 2022 03h55 HE
|
BioNTech SE
BNT211 kombiniert zwei innovative Ansätze in Form von einer Therapie: eine autologe CAR-T-Zelltherapie, die das onkofetale Antigen Claudin 6 (CLDN6) adressiert und einen für CLDN6-kodierenden...
BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR
11 avr. 2022 03h55 HE
|
BioNTech SE
BNT211 combines two innovative approaches in one regimen, an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine...
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors
05 avr. 2022 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced...
Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting
04 avr. 2022 10h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today two...